GAUDIUMIVFBSEGaudium IVF and Women Health LtdHighNeutral
Announced Fri, 29 May · 01:58 IST

Press Release on Audited Financial Results for the quarter and year March 31, 2026

Revenue Growth 20pctEbitda Margin CompressionResults View source PDF

GAUDIUMIVF · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.8%1-day move
₹116.79
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.8-3.8-5.7-7.6-9.4-9.5-6.9-5.1
Up moveDown movePending
AI summary

Gaudium IVF reported strong Q4FY26 results with revenue of ₹30.35 Cr (up 12.74% YoY), EBITDA of ₹12.17 Cr (up 39.56% YoY with 40.10% margin), and PAT of ₹8.36 Cr (up 29.46% YoY). For full year FY26, revenue stood at ₹104.35 Cr, up 47.56% YoY from ₹70.72 Cr, driven by higher patient volumes at mature hubs and high clinical success rates. FY26 EBITDA grew to ₹37.70 Cr (up 31.69% YoY) while PAT reached ₹24.48 Cr (up 27.69% YoY). The company became India's first IVF chain to integrate AI-led embryology through a partnership with UK-based IVF 2.0, deploying SiD and ERICA platforms. Gaudium maintains 7 hubs and 28 spokes with a 58% clinical pregnancy success rate.

Likely market impact

Strong financial performance with near 48% revenue growth demonstrates robust execution; however, full-year EBITDA margin compressed to 36.13% from 40.48% in FY25, which could concern margin-focused investors despite improved Q4 margins.